Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Kura Oncology, Inc. before investing.

In this article, we go over a few key elements for understanding Kura Oncology, Inc.’s stock price such as:

• Kura Oncology, Inc.’s current stock price and volume
• Why Kura Oncology, Inc.’s stock price changed recently
• Upgrades and downgrades for KURA from analysts
• KURA’s stock price momentum as measured by its relative strength

About Kura Oncology, Inc. (KURA)

Before we jump into Kura Oncology, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Want to learn more about Kura Oncology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Kura Oncology, Inc..

Kura Oncology, Inc.’s Stock Price as of Market Close

As of May 13, 2026, 9:31 AM, CST, Kura Oncology, Inc.’s stock price was $8.862.

Kura Oncology, Inc. is down 8.45% from its previous closing price of $9.680.

During the last market session, Kura Oncology, Inc.’s stock traded between $8.840 and $9.000. Currently, there are approximately 88.05 million shares outstanding for Kura Oncology, Inc..

Kura Oncology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Kura Oncology, Inc. Stock Price History

Kura Oncology, Inc.’s (KURA) price is currently up 0.37% so far this month.

During the month of May, Kura Oncology, Inc.’s stock price has reached a high of $9.940 and a low of $8.670.

Over the last year, Kura Oncology, Inc. has hit prices as high as $12.490 and as low as $5.450. Year to date, Kura Oncology, Inc.’s stock is down 14.7%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Kura Oncology, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 12, 2026, there were 2 analysts who downgraded Kura Oncology, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Kura Oncology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Kura Oncology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Kura Oncology, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Kura Oncology, Inc. (KURA) by visiting AAII Stock Evaluator.

Relative Price Strength of Kura Oncology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 12, 2026, Kura Oncology, Inc. has a weighted four-quarter relative price strength of 11.12%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how Kura Oncology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Kura Oncology, Inc. Stock Price: Bottom Line

As of May 13, 2026, Kura Oncology, Inc.’s stock price is $8.862, which is down 8.45% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Kura Oncology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.